Cannara Announces Proposed Settlement of Convertible Debenture via Share Issuance
Cannara Biotech (OTCQB: LOVFF), a vertically integrated cannabis producer, has announced plans to settle approximately $6.2 million of debt through a share issuance. The settlement includes $4.7 million in principal and $1.5 million in accrued interest under its convertible debenture with Olymbec Investments.
The company will issue 3,462,763 common shares at a deemed price of $1.80 per share, with 851,652 shares representing interest payment. Upon completion, Olymbec will hold approximately 25.47% of Cannara's outstanding shares. The transaction requires TSX Venture Exchange approval and qualifies for exemption from minority shareholder approval requirements.
Additionally, Cannara granted 40,000 stock options to Bristol Capital for investor relations services, exercisable at $1.80 per share until April 25, 2028.
Cannara Biotech (OTCQB: LOVFF), un produttore di cannabis verticalmente integrato, ha annunciato piani per sanare circa 6,2 milioni di dollari di debito mediante un'emissione di azioni. L'accordo comprende 4,7 milioni di dollari in capitale e 1,5 milioni di dollari di interessi maturati ai sensi della sua obbligazione convertibile con Olymbec Investments.
L'azienda emetterà 3.462.763 azioni ordinarie a un prezzo ritenuto di 1,80 dollari per azione, con 851.652 azioni che rappresentano il pagamento degli interessi. Al completamento, Olymbec possederà circa il 25,47% delle azioni in circolazione di Cannara. L'operazione richiede l'approvazione della TSX Venture Exchange e beneficia di un'esenzione dall'approvazione dei soci di minoranza.
Inoltre, Cannara ha concesso 40.000 stock option a Bristol Capital per servizi di relazioni con gli investitori, esercitabili a 1,80 dollari per azione fino al 25 aprile 2028.
Cannara Biotech (OTCQB: LOVFF), un productor de cannabis verticalmente integrado, ha anunciado planes para saldar aproximadamente 6,2 millones de dólares de deuda mediante una emisión de acciones. El acuerdo incluye 4,7 millones de dólares en principal y 1,5 millones de dólares en intereses devengados bajo su bono convertible con Olymbec Investments.
La empresa emitirá 3.462.763 acciones comunes a un precio considerado de 1,80 dólares por acción, con 851.652 acciones que representan el pago de intereses. Al completarse, Olymbec poseerá aproximadamente el 25,47% de las acciones en circulación de Cannara. La operación requiere la aprobación de la TSX Venture Exchange y califica para exención de la aprobación de accionistas minoritarios.
Además, Cannara otorgó 40.000 opciones sobre acciones a Bristol Capital por servicios de relaciones con inversionistas, ejercitables a 1,80 dólares por acción hasta el 25 de abril de 2028.
Cannara Biotech (OTCQB: LOVFF)은 수직적으로 통합된 대마초 생산자로, 약 620만 달러의 채무를 주식 발행으로 해결할 계획을 발표했습니다. 이번 합의에는 주요 부채 470만 달러와 누적 이자 150만 달러가 포함되며, 이는 Olymbec Investments와의 전환형 약정에 따른 것입니다.
회사는 3,462,763주의 보통주를 주당 1.80달러로 평가하여 발행하며, 이 중 851,652주는 이자 지급분입니다. 완료 시 Olymbec는 Cannara의 발행 주식의 약 25.47%를 보유하게 됩니다. 이 거래는 TSX Venture Exchange의 승인을 필요로 하며 소수주주 승인의 면제 대상입니다.
또한 Cannara는 투자자 관계 서비스를 위해 Bristol Capital에 40,000주식 옵션을 부여했으며, 행사가는 주당 1.80달러, 만료일은 2028년 4월 25일입니다.
Cannara Biotech (OTCQB: LOVFF), un producteur de cannabis intégré verticalement, a annoncé son intention de solder environ 6,2 millions de dollars de dette par une émission d'actions. L'accord comprend 4,7 millions de dollars de principal et 1,5 million de dollars d'intérêts accumulés en vertu de son obligataire convertible avec Olymbec Investments.
L'entreprise émettra 3 462 763 actions ordinaires à un prix présumé de 1,80 dollar par action, dont 851 652 actions représentent le paiement des intérêts. À l'achèvement, Olymbec détiendra approx. 25,47% des actions en circulation de Cannara. La transaction nécessite l'approbation de la TSX Venture Exchange et bénéficie d'une exemption de l'approbation des actionnaires minoritaires.
De plus, Cannara a accordé 40 000 options sur actions à Bristol Capital pour des services de relations avec les investisseurs, exerçables à 1,80 dollar par action jusqu’au 25 avril 2028.
Cannara Biotech (OTCQB: LOVFF), ein vertikal integrierter Cannabis-Produzent, hat Pläne bekannt gegeben, etwa 6,2 Mio. USD Schulden durch eine Aktienausgabe zu begleichen. Die Einigung umfasst 4,7 Mio. USD Kapital und 1,5 Mio. USD aufgelaufene Zinsen gemäß seiner Wandelanleihe mit Olymbec Investments.
Das Unternehmen wird 3.462.763 Stammaktien zu einem bewerteten Preis von 1,80 USD pro Aktie ausgeben, wobei 851.652 Aktien den Zinszahlungen entsprechen. Nach Abschluss wird Olymbec etwa 25,47% der ausstehenden Cannara-Aktien halten. Die Transaktion bedarf der Genehmigung der TSX Venture Exchange und ist von der Genehmigung durch Minderheitsaktionäre befreit.
Zusätzlich hat Cannara Bristol Capital 40.000 Aktienoptionen für Investor-Relations-Dienstleistungen eingeräumt, ausübbar zu 1,80 USD pro Aktie bis zum 25. April 2028.
Cannara Biotech (OTCQB: LOVFF)، منتِج القنب رأسيًا متكامل، أعلن عن خطط لتسديد نحو 6.2 ملايين دولار من الدين من خلال إصدار أسهم. وشمل التسوية 4.7 ملايين دولار كاصل الدين و 1.5 مليون دولار من الفوائد المتراكمة بموجب سندها القابل للتحويل مع Olymbec Investments.
ستنطلق الشركة في إصدار 3,462,763 سهماً عادياً بسعر مُقدر قدره 1.80 دولار للسهم، مع تمثيل 851,652 سهماً دفع الفوائد. عند الاكتمال، ستملك Olymbec نحو 25.47% من أسهم Cannara القائمة. تتطلب الصفقة موافقة بورصة TSX Venture وتؤهل للإعفاء من متطلبات موافقة المساهمين الأقلية.
بالإضافة إلى ذلك، منحت Cannara 40,000 خيار أسهم لـ Bristol Capital مقابل خدمات العلاقات مع المستثمرين، قابلة لممارسة عند 1.80 دولار للسهم حتى 25 أبريل 2028.
Cannara Biotech (OTCQB: LOVFF)，一家垂直整合的大麻产品生产商，宣布计划通过发行股份来清偿约620万美元的债务。此次和解包括470万美元的本金和150万美元的应计利息，基于其与Olymbec Investments的可转换公司债。
公司将以被视为价格为1.80美元/股的价格发行3,462,763股普通股，其中851,652股用于利息支付。完成后，Olymbec将持有Cannara已发行股份的约25.47%。此交易需要TSX Venture Exchange的批准，并符合豁免少数股东批准的条件。
此外，Cannara向Bristol Capital授予了40,000股股票期权，用于投资者关系服务，行权价为每股1.80美元，有效期至2028年4月25日。
- Debt reduction of $6.2 million improves balance sheet structure
- Settlement through equity preserves cash for operations
- Company previously demonstrated ability to reduce debt with $1 million principal repayment in June 2025
- Significant dilution with 3,462,763 new shares being issued
- Increased ownership concentration with Olymbec controlling 25.47% post-transaction
- Related party transaction with significant influence from non-independent director
MONTREAL, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at disruptive prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced its intention to settle an aggregate of approximately
The Olymbec Convertible Debenture was originally issued in the total principal amount of
The Company proposes to satisfy the outstanding indebtedness through the issuance of 3,462,763 common shares of Cannara (“Common Shares”), 851,652 of which represent the repayment of interest owing, at a deemed issuance price of
The Proposed Olymbec Share Issuance is subject to the terms and conditions set forth in the policies of the TSX Venture Exchange (“TSXV”) and the completion of the shares for debt transaction, as well as the issuance of the Common Shares, remains subject to the review and approval of the TSXV.
Mr. Derek Stern, a non-independent director of the Company, holds a significant interest in Olymbec and is a control person of the Company. The Common Shares issued to Olymbec will be deemed a “related party transaction” in accordance with TSXV Policy 5.9 and Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). Cannara intends to rely on an available exemption pursuant to MI 61-101 from the minority shareholder approval and valuation requirements for the Proposed Olymbec Share Issuance as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves interested parties, exceeds
Following completion of the Proposed Olymbec Share Issuance, Olymbec will hold 23,792,920 Common Shares of the Company, and Mr. Derek Stern, a non-independent director of the Company, will personally hold 376,040 Common Shares. Collectively, these direct and indirect holdings will represent 24,168,960 Common Shares, or approximately
The Proposed Olymbec Share Issuance has been approved by the directors of the Company who are independent in connection with the Proposed Olymbec Share Issuance.
For a full description of the Olymbec Convertible Debenture, please refer to the Company’s Annual Information Form for the fiscal year ended August 31, 2024. A copy of the Olymbec Convertible Debenture is available under the Company’s profile on SEDAR+ at www.sedarplus.ca .
Grant of Options in Connection with Investor Relations Services
With reference to its press release dated April 28, 2025, the Company provides the following clarification. In connection with the renewal of an investor relations agreement originally disclosed via news release on May 4, 2022, the Company has granted Bristol Capital Ltd. (“Bristol”) 40,000 stock options. Each option is exercisable at a price of
CONTACT
| Nicholas Sosiak, CPA, CA Chief Financial Officer nick@cannara.ca | Zohar Krivorot President & Chief Executive Officer zohar@cannara.ca |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
ABOUT CANNARA
Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), is a vertically integrated producer of affordable premium-grade cannabis products for the Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,650,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Leveraging Québec’s low electricity costs, Cannara’s facilities produce premium-grade cannabis products at an affordable price. For more information, please visit cannara.ca.
CAUTIONARY STATEMENT REGARDING “FORWARD-LOOKING” INFORMATION
This news release may contain “forward-looking information” within the meaning of Canadian securities legislation (“forward-looking statements”). These forward-looking statements are made as of the date of this MD&A and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. All statements other than statements of historical facts included in this document constitute forward-looking information, including but not limited to statements with respect to the Proposed Olymbec Share Issuance.
Forward-looking statements relate to future events or future performance and reflect Company management’s expectations or beliefs regarding future events and include, but are not limited to, the Company and its operations, its projections or estimates about its future business operations, its planned expansion activities, anticipated product offerings, the adequacy of its financial resources, the ability to adhere to financial and other covenants under lending agreements, future economic performance, and the Company’s ability to become a leader in the field of cannabis cultivation, production, and sales.
In certain cases, forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur” or “be achieved” or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including “may,” “future,” “expected,” “intends” and “estimates.” By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in, or implied by, such forward-looking information. These risks and uncertainties include, but are not limited to, the risk factors which are discussed in greater detail under “Risk Factors” in the Company’s AIF available on SEDAR+ at www.sedarplus.ca and under the “Investor Area” section of our website at https://www.cannara.ca/en/investor-area.
Other risks not presently known to the Company or that the Company believes are not significant could also cause actual results to differ materially from those expressed in its forward-looking statements. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, readers are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions were made in preparing the forward-looking information concerning the availability of capital resources, business performance, market conditions, as well as customer demand. Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein is provided as of the date hereof, and we do not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.
FAQ
How much debt is Cannara Biotech (LOVFF) settling through share issuance?
What is the share price for Cannara's debt settlement?
How many shares will Olymbec own after the debt settlement?
What stock options did Cannara grant to Bristol Capital?
Does the debt settlement require shareholder approval?
